PAA.AX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 02:10):

PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally...

Stats
Today's Volume	6.95M
Average Volume	1.47M
Market Cap	92.83M
EPS	$0 ( 2024-02-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-11.75
ATR14	$0.00200 (0.85%)

Volume Correlation

Long: -0.14 (neutral)

Short: 0.41 (neutral)

Signal:(40.11) Neutral

Pharmaust Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pharmaust Ltd Correlation - Currency/Commodity

0.31
( neutral )

0.03
( neutral )

0.00
( neutral )

0.66
( moderate )

Pharmaust Ltd Financials

Annual	2023
Revenue:	$2.82M
Gross Profit:	$-929 535 (-32.92 %)
EPS:	$-0.0194

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.00110

Q4	2023
Revenue:	$908 813
Gross Profit:	$-1.14M (-125.19 %)
EPS:	$-0.0193

Q3	2022
Revenue:	$455 497
Gross Profit:	$-128 001 (-28.10 %)
EPS:	$-0.00720

Financial Reports:

No articles found.

Pharmaust Ltd

PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. The company has a research agreement with the Walter and Eliza Hall Institute to investigate the effects of MPL upon human T-lymphotrophic virus-1 (HTLV-1) infections in vitro. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.